R&D News | pharmaphorum

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J begins trial of two-dose COVID-19 vaccine regimen

Johnson & Johnson has begun a second phase 3 trial of its potential COVID-19 vaccine, including sites in the UK, testing whether it works as a two-dose regimen.

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

UCB revs up its gene therapy drive with Handl acquisition

UCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get control of its adeno-associated virus (AAV) capsid delivery platform and two research

News

Switzerland’s Synendos raises CHF 20m for CNS drug developme...

Swiss startup Synendos Therapeutics has raised CHF 20 million (almost $22 million) in first-round financing that will be used to develop its endocannabinoid drugs for central nervous system

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer axes IPF deal with South Korea's Bridge Biotherap...

Boehringer Ingelheim and South Korea’s Bridge Biotherapeutics have decided to axe their collaboration over a potential new drug for idiopathic pulmonary fibrosis (IPF), BBT-877.

News

Russia claims 92% efficacy for Sputnik COVID-19 shot

In the second positive piece of COVID-19 vaccine news in a week, Russia’s Sputnik V candidate has been shown to be 92% effective at the interim point of a 40,000-patient study.

News

Pfizer/BioNTech say vaccine works in 90% of COVID-19 patient...

As the death toll from COVID19 inexorably mounts, Pfizer and BioNTech have announced that their COVID-19 vaccine candidate is more than 90% effective at countering the disease in an interim

J&J begins trial of two-dose COVID-19 vaccine regimen

UCB revs up its gene therapy drive with Handl acquisition

Switzerland’s Synendos raises CHF 20m for CNS drug developme...

Boehringer axes IPF deal with South Korea's Bridge Biotherap...

Russia claims 92% efficacy for Sputnik COVID-19 shot

Pfizer/BioNTech say vaccine works in 90% of COVID-19 patient...

Hengrui gets world-first okay for platelet drug hetrombopag

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks